Don’t miss – Page 158 – Endpoints News

SIGN UP

Novavax teases Covid-19 vaccine trial design as it kicks off UK study — US to follow next month

3 years ago

Covid-19 roundup: Operation Warp Speed's 7th vaccine is live attenuated; Small biotech touts big success where giants have failed

3 years ago

Only five months after a Series A launch, Taysha goes public with $157M IPO

3 years ago

Flagship's next big technological bet? The cloud

3 years ago

PhII Alzheimer's failure deals new blow to Roche, AC Immune — but the tau hypothesis is far from dead

3 years ago

Covid-19 roundup: J&J begins pivotal Phase III trial for vaccine; Controversial human challenge trials to begin in London — report

3 years ago

Still held down by clinical hold, Novartis' Zolgensma falls further behind Biogen and Roche as FDA asks for a new pivotal study

3 years ago

As its biotechs hit the pandemic exit, Longitude raises $585M for new neuro, cancer, aging and orphan-focused fund

3 years ago

Blueprint plots return to FDA with new Ayvakit data in rare condition — and the analysts cheer

3 years ago

After bruising rejection, bluebird and Bristol Myers Squibb land ide-cel priority review. But will it matter for the CVR?

3 years ago

Medicxi's David Grainger and Francesco De Rubertis pump €200M into six companies and what they say is a first-of-its kind fund

3 years ago

Rocked by customs investigation, Legend's CFO takes over as CEO Frank Zhang placed under house arrest

3 years ago

Two wild weeks for Grail end in $8B Illumina buyout

3 years ago

Roche vaults to the front of the NLRP3 clinical race, paying $448M upfront to bag Inflazome

3 years ago

#ESMO20: Eli Lilly shows off the data for its Verzenio success. Was it worth $18 billion?

3 years ago

#ESMO20: It’s not just Keytruda anymore — Merck spotlights 3 top early-stage cancer drugs

3 years ago

#ESMO20: Amgen team nails down solid early evidence of AMG 510’s potential for NSCLC, unlocking the door to a wave of KRAS programs

3 years ago

#ESMO20: Trodelvy data show that Gilead's $21B buyout may have been worth the big premium

3 years ago

#ESMO20: Look out Merck. Bristol Myers and Exelixis stake out their combo’s claim to best-in-class status for frontline kidney cancer

3 years ago

#ESMO20: Autolus provides glimpse of next-generation CAR-T program, showing early positive safety data

3 years ago

A micro-cap with a potentially promising coronavirus drug enlists mask-skeptic congressman for DSMB

3 years ago

#ESMO20: Alkermes offers their first snapshot of a benefit for their next-gen IL-2 drug. But why did 1 patient starve to death?

3 years ago

Pfizer matches Moderna with their full Covid-19 trial blueprint — AstraZeneca says it will unveil its protocol 'shortly'

3 years ago

Covid-19 roundup: AlloVir snags IND approval for potential T cell therapy; Sanofi and GSK strike 300 million-dose deal with the EU

3 years ago

First page Previous page 155 156 157158159 160 161 Next page Last page